Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small cell lung cancer (START): A randomized, double-blind, phase III trial

Journal of Thoracic Disease

Volumn 6, Issue 6, 2014, Pages 571-573

  DeGregorio, Michael ^a   Soe, Lin ^b   Wolf, Michael ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Marshall Hospital   (United States)

^c Merck Serono GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; MUCIN 1; PLACEBO; PLATINUM DERIVATIVE; TECEMOTIDE;

ANTIGEN PRESENTING CELL; CANCER STAGING; CHEMORADIOTHERAPY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; EDITORIAL; HUMAN; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN GLYCOSYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); TH1 CELL; TREATMENT RESPONSE; TUMOR IMMUNITY;

EID: 84904903954     PISSN: 20721439     EISSN: 20776624     Source Type: Journal    
DOI: 10.3978/j.issn.2072-1439.2014.05.15     Document Type: Editorial

References (11)

1. Lwin Z, Riess JW, Gandara D. The continuing role of chemotherapy for advanced non-small cell lung cancer in the targeted therapy era. J Thorac Dis 2013;5:S556-S564.
2. Butts C, Socinski MA, Mitchell PL, et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol 2014;15:59-68.
3. Hanisch FG, Schwientek T, Von Bergwelt-Baildon MS, et al. O-Linked glycans control glycoprotein processing by antigen-presenting cells: a biochemical approach to the molecular aspects of MUC1 processing by dendritic cells. Eur J Immunol 2003;33:3242-54.
4. Hiltbold EM, Alter MD, Ciborowski P, et al. Presentation of MUC1 tumor antigen by class I MHC and CTL function correlate with the glycosylation state of the protein taken Up by dendritic cells. Cellular Immunology 1999;194:143-9.
5. Purcell AW, van Driel IR, Gleeson PA. Impact of glycans on T-cell tolerance to glycosylated self-antigens. Immunology and Cell Biology 2008;86:574-9.
6. Green DR, Ferguson T, Zitvogel L, et al. Immunogenic and tolerogenic cell death. Nat Rev Immunol 2009;9:353-63.
7. Kao CJ, Wurz GT, Monjazeb AM, et al. Antitumor effects of cisplatin combined with tecemotide immunotherapy in a human MUC1 transgenic lung cancer mouse model. Cancer Immunol Res 2014;2:581-9.
8. Kao CJ, Wurz GT, Schröder A, et al. Clarifying the pharmacodynamics of tecemotide (L-BLP25)-based combination therapy. Oncoimmunology 2013;2:e26285.
9. Wurz GT, Gutierrez AM, Greenberg BE, et al. Antitumor effects of L-BLP25 Antigen-Specific tumor immunotherapy in a novel human MUC1 transgenic lung cancer mouse model. J Transl Med 2013;11:64.
10. + T cells induced by melanoma vaccines. Cancer Res 2014;74:1045-55.
11. Ramlogan-Steel CA, Steel JC, Morris JC. Lung cancer vaccines: current status and future prospects. Transl Lung Cancer Res 2014;3:46-52.